Increased IL-35 serum levels in systemic sclerosis and association with pulmonary interstitial involvement

Clinical Rheumatology

Volumn 34, Issue 9, 2015, Pages 1621-1625

  Dantas, Andréa Tavares ^a,b   Gonçalves, Sayonara Maria Calado ^a   Pereira, Michelly Cristiny ^a   Gonçalves, Rafaela Silva Guimarães ^a,b   Marques, Cláudia Diniz Lopes ^b   Rego, Moacyr Jesus Barreto de Melo ^a   da Rocha Pitta, Ivan ^a   Duarte, Angela Luzia Branco Pinto ^b   da Rocha Pitta, Maira Galdino ^a  

^a Laboratório de Imunomodulação e Novas Abordagens Terapêuticas   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Cytokine; Interleukin 35; Pulmonary fibrosis; Systemic sclerosis

Indexed keywords

INTERLEUKIN 35; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC SCLEROSIS; AGED; BLOOD; CASE CONTROL STUDY; LUNG FIBROSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84940203172     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-3006-y     Document Type: Article

References (21)

1. Fenoglio D, Bernuzzi F, Battaglia F, Parodi A, Kalli F, Negrini S, De Palma R, Invernizzi P, Filaci G (2012) Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev 12(2):300–304
2. Slobodin G, Ahmad MS, Rosner I, Peri R, Rozenbaum M, Kessel A, Toubi E, Odeh M (2010) Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 261(2):77–80
3. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169):566–569
4. Ning-Wei Z (2010) Interleukin (IL)-35 is raising our expectations. Rev Med Chil 138(6):758–766
5. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Hermine A, Devergne O (2008) Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 181(10):6898–6905
6. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, Gutchigian S, Frisch A, Hodge I, Jiang X et al (2012) IL-35 is a novel responsive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines. PLoS One, 7(3):e33628
7. Banchereau J, Pascual V, O'Garra A (2012) From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 13(10):925–931
8. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY (2007) IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37(11):3021–3029
9. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW (2010) IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 184(12):7144–7153
10. Wirtz S, Billmeier U, McHedlidze T, Blumberg RS, Neurath MF (2011) Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 141(5):1875–1886
11. Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980) Subcommittee for scleroderma criteria of the american rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum 23(5):581–590
12. LeRoy EC, Medsger TA (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573–1576
13. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22(7):1281–1285
14. Ouyang H, Shi YB, Liu ZC, Wang Z, Feng S, Kong SM, Lu Y (2014) Decreased interleukin 35 and CD4 + EBI3+ T cells in patients with active systemic lupus erythematosus. Am J Med Sci 348(2):156–161
15. Qiu F, Song L, Yang N, Li X (2013) Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus 22(10):1011–1016
16. Senolt L, Filkova M, Hulejova H, Cerezo LA, Pecha O, Plestilova L, Jarosova K, Pavelka K, Vencovsky J, Mann HF (2011) Decrease of serum IL-35 predicts clinical improvement in patients with very early RA [abstract]. Arthritis Rheum, 63(Suppl 10)
17. Filkova M, Hulejova H, Polanska M, Cerezo LA, Vencovsky J, Pavelka K (2010) Pro-Inflammatory properties of IL-35 and its association with disease activity in patients with rheumatoid arthritis [abstract]. Arthritis Rheum, 62(Suppl 10)
18. Giovannetti A, Rosato E, Renzi C, Maselli A, Gambardella L, Giammarioli AM, Palange P, Paoletti P, Pisarri S, Salsano F et al (2010) Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol 137(1):122–133
19. Liu X, Gao N, Li M, Xu D, Hou Y, Wang Q, Zhang G, Sun Q, Zhang H, Zeng X (2013) Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS One 8:e64531, United States
20. Jiang N, Li M, Zeng X (2014) Correlation of Th17 cells and CD4(+)CD25(+) regulatory T cells with clinical parameters in patients with systemic sclerosis. Chin Med J (Engl) 127(20):3557–3561
21. Ishida T, Kotani T, Takeuchi T, Makino S (2012)Pulmonary toxicity after initiation of azathioprine for treatment of interstitial pneumonia in a patient with rheumatoid arthritis. In: J Rheumatol. vol. 39. Canada, 1104-1105